Exploring the globoid cell leukodystrophy protein network and therapeutic interventions.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Globoid cell leukodystrophy is a rare, severe white matter disorder causing progressive neurological decline.
• Current therapeutic interventions for this condition are extremely limited.

Purpose of the Study:

• To identify druggable targets and potential small molecule therapeutics for Globoid cell leukodystrophy.
• To analyze the disease-associated neuronal protein interaction network.

Main Methods:

• Differential gene expression analysis to identify disease-associated genes (p < 0.05, |Fc| > 1).
• Construction and analysis of a neuronal protein circuit to identify core protein nodes.
• In silico drug discovery including molecular docking and dynamics simulations to evaluate T-5224 efficacy against the Jun/CRE complex.

Main Results:

• Five core protein nodes (FOS, FOSB, GDNF, GFRA1, JUN) were identified in the disease network.
• The small molecule T-5224 demonstrated significant binding affinity to the Jun/CRE complex (binding energy: -11.0 kcal/mol).
• Molecular dynamics simulations confirmed stable hydrophilic interactions and structural integrity of the T-5224-Jun/CRE complex.

Conclusions:

• JUN is a pivotal protein in Globoid cell leukodystrophy pathogenesis, making the Jun/CRE complex a promising therapeutic target.
• T-5224 shows potential as a therapeutic agent for Globoid cell leukodystrophy by inhibiting c-Jun activity.
• Further in vitro and in vivo studies are proposed to validate T-5224's therapeutic potential.